News News Details

Efung Capital Holds Successful Election Congress for Renewal of Party Branch Committee Secretary

Date: 2025-07-15
Views: 0

On July 15, 2025, the election congress for the renewal of the Secretary of the Party Branch Committee of Shenzhen Efung Investment Management Enterprise (Limited Partnership) of the Communist Party of China was grandly convened amid the solemn national anthem.

In strict accordance with election procedures, Comrade Li Yajing, Managing Director of the Company, was elected Secretary of the new Party Branch Committee of Shenzhen Efung Investment Management Enterprise (Limited Partnership) of the Communist Party of China through secret ballot and competitive election.
The newly elected Secretary Li Yajing stated: She will always give top priority to the Party’s political construction, take the lead in thoroughly studying and implementing Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, earnestly strengthen the "Four Consciousnesses", enhance the "Four Matters of Confidence", and uphold the "Two Maintenances", ensuring that the work of the Party branch always advances along the correct political direction. Meanwhile, she will actively organize Party members to carry out various political learning activities, continuously improve their political awareness and theoretical level, and enable every Party member to become a mainstay in enterprise development and a vanguard force driving social progress.
The congress concluded successfully amid the solemn Internationale. As a pioneer in China’s biomedical investment sector, Efung Capital will take this renewal as a new starting point, fully leverage the guiding role of Party building, use the Party’s innovative theories to guide practice, promote in-depth integration of Party building and business, and drive the company to,achieve high-quality development.


Related News / Recommended news More
2026 - 03 - 24
In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...
2026 - 03 - 25
Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...
2026 - 03 - 06
Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...
2026 - 03 - 05
The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务